References
Pastore S, Stocco G, Moressa V, Zandona L, Favretto D, Malusa N et al (2015) 5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis. Rheumatol Int 35(4):619–627
Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R et al (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 35(4):572–579
Goldman J, Becker ML, Jones B, Clements M, Leeder JS (2011) Development of biomarkers to optimize pediatric patient management: what makes children different? Biomark Med 5(6):781–794
Malik F, Ranganathan P (2013) Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. Pharmacogenomics 14(3):305–314
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The author declares that she has no conflict of interest.
Rights and permissions
About this article
Cite this article
Ranganathan, P. Genetic variants influencing response to methotrexate in juvenile idiopathic arthritis and rheumatoid arthritis. Rheumatol Int 36, 53–54 (2016). https://doi.org/10.1007/s00296-015-3318-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-015-3318-x